Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2355598 | 0.89 | TAAR1 (0.40) | MAPTRAB9AATML3MBTL1TAAR1 | |
| SCHEMBL19254235 | 0.88 | CTRC (0.44) | MAPTRAB9AATML3MBTL1TAAR1 | |
| SCHEMBL21448651 | 0.86 | AKR1C2 (0.40) | MAPTATML3MBTL1HPGDP2RX3 | |
| SCHEMBL17586140 | 0.84 | TYR (0.47) | MAPTRAB9AATML3MBTL1KMT2A | |
| SCHEMBL13806110 | 0.83 | TAAR1 (0.41) | MAPTRAB9AATML3MBTL1TAAR1 | |
| SCHEMBL8230054 | 0.82 | GRIN2D (0.41) | MAPTRAB9AATML3MBTL1HPGD | |
| SCHEMBL18252847 | 0.81 | TAAR1 (0.59) | TAAR1HTR2ACYP1A2 | |
| SCHEMBL9174302 | 0.81 | TAAR1 (0.35) | MAPTRAB9AATML3MBTL1TAAR1 | |
| SCHEMBL10822907 | 0.81 | HPGD (0.36) | MAPTRAB9AATML3MBTL1TAAR1 | |
| SCHEMBL9174310 | 0.81 | IDO1 (0.42) | MAPTRAB9AATML3MBTL1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3524600-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS | Sanofi (FR) | 2019-08-14 | — | — | EP | disclosed |
| US-9646641-B2 | Composition for magnetic recording medium and magnetic recording medium | FUJIFIM CORPORATION (JP) | 2017-05-09 | — | — | US | disclosed |
| US-9149463-B2 | Methods and compositions of treating a Flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-14 | — | — | US | disclosed |
| US-20110052536-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| US-20100260717-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-14 | — | — | US | disclosed |
| EP-1960398-B1 | ARYL ACETIC ACID AND ESTER DERIVATIVES AND THEIR USES AS ANTIINFLAMMATORY | NOVARTIS AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-01-21 | — | — | US | disclosed |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-19 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052536-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, RNGTT | MAPT 4352/4885RAB9A 3148/4885ATM 4574/4885 |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | MAPT 4569/4885RAB9A 2617/4885ATM 4431/4885 |
| US-20100260717-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | HAVCR2, MAVS, EIF2AK2 | MAPT 2810/4885RAB9A 3170/4885ATM 4614/4885 |
| US-20100015093-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | MAPT 4569/4885RAB9A 2617/4885ATM 4431/4885 |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MAPT 4649/4885RAB9A 160/4885ATM 3408/4885 |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NSUN3, RNGTT, NSUN2 | MAPT 4638/4885RAB9A 3558/4885ATM 4784/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | MAPT 4569/4885RAB9A 2617/4885ATM 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.